MECHANO-THERAPEUTICS

A Novel Therapeutic Platform for Human Diseases

Our Team is Positioned to be the Leader in the Discovery and Development of Mechano-Therapeutics, First-in-Class Drugs Designed To Inhibit Novel Targets Driving Pathologic Cell Behavior in Cancer and Fibrosis

Our Mission

Leveraging Decades of World-leading Expertise in Mechanobiology and a Unique Discovery Platform, Zenon is Dedicated to the Discovery and Development of Innovative Mechano-Therapeutics, First in Class Drugs to Treat Unmet Clinical Needs or Improved Outcomes for Patients

Our Programs

Zenon’s Drug Discovery Programs target Cellular Mechano-Sensors in Cancer and Fibrosis. These Novel Disease Intervention Points were Identified by Zenon’s Founder and CEO, David Lagares, at Harvard Medical School

Meet Our Team

World-leading Expertise in Mechanobiology